Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results

Core Viewpoint - Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is identified as a stock with significant upside potential, with Guggenheim initiating coverage with a "Buy" rating and a price target of $8.00, indicating a potential increase of 146.5% from the current price [1] Group 1: Company Overview - Black Diamond Therapeutics, Inc. is a clinical-stage oncology company founded in 2014, based in Cambridge, Massachusetts, focusing on discovering and developing MasterKey therapies for genetically defined tumors [3] - The company has outperformed the market by nearly 40% year-to-date, suggesting a favorable investment opportunity as the stock may experience substantial rallies [3] Group 2: Product Pipeline and Expectations - Analysts have high expectations for the company's silevertinib Phase 2 data, which is anticipated in the second half of 2025 [1] - Silevertinib's preclinical profile is designed for broad-spectrum mutation selectivity over wild-type EGFR, aiming to achieve a 50% objective response rate (ORR) and a 10-month median progression-free survival (mPFS) [2] - The strong second-line response rates after osimertinib treatment may attract strategic partnerships in the future [2]